belimumab是一种抑制B淋巴细胞刺激剂的单克隆抗体，用于系统性红斑狼疮患者的III期随机、安慰剂对照研究

{"title":"belimumab是一种抑制B淋巴细胞刺激剂的单克隆抗体，用于系统性红斑狼疮患者的III期随机、安慰剂对照研究","authors":"R. Panush","doi":"10.1016/J.YMED.2012.09.010","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23907,"journal":{"name":"Yearbook of Medicine","volume":"23 1","pages":"17-18"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus\",\"authors\":\"R. Panush\",\"doi\":\"10.1016/J.YMED.2012.09.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23907,\"journal\":{\"name\":\"Yearbook of Medicine\",\"volume\":\"23 1\",\"pages\":\"17-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Yearbook of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/J.YMED.2012.09.010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yearbook of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/J.YMED.2012.09.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}